血液疾病研究及治療 | 合法藥品大搜索

台灣FDA於2018年8月核准emicizumab，適應症為：用於帶有第Ⅷ凝血因子抗體的A型血友病病人之出血事件常規性預防，emicizumab的起始劑量為：3 mg/kg SC每 ... Read More

2019年10月16日 — 含emicizumab 成分治療第八凝血因子抗體之A 型血友病之新成分新藥「Hemlibra SC injection」，會中決定： 同意健保署初核結果如下： 1.A 型血 ... Read More

健保署公告：暫予支付含emicizumab成分藥品Hemlibra SC injection 30mg/mL及 150mg/mL（emicizumab）共2品項暨其藥品給付規定（自108年11月1日生效） ... Read More

Emicizumab (trade name Hemlibra) is a humanized bispecific antibody for the treatment of haemophilia A, developed by Genentech and Chugai (a subsidiary of ... Read More

由 HA Blair 著作 · 2019 · 被引用 22 次 — Emicizumab (Hemlibra®), a recombinant, humanized, bispecific monoclonal antibody, restores the function of missing activated factor VIII (FVIII) by bridging FIXa ... Read More

由 P Knoebl 著作 · 被引用 14 次 — Emicizumab is a bispecific, FVIII-mimetic therapeutic antibody that reduced the annualized bleeding rates in congenital hemophiliacs. Here, we ... Read More

2018年5月23日 — 日本中外製藥5月22日宣佈，在日本國內上市了A型血友病的治療藥「Hemlibra」（通用名emicizumab-kxwh）。 · Hemlibra採用以1個抗體與2種抗原 ... Read More

Learn about HEMLIBRA® (emicizumab-kxwh), a hemophilia A treatment approved for people with hemophilia A with or without factor VIII inhibitors. See full ... Read More

Hemlibra (emicizumab) ... Hemlibra is a bispecific factor IXa- and factor X-directed antibody. It is designed to bring together factor IXa and factor X, proteins required ... Read More